Provides scientific/clinical expertise and leadership specific to the Inflammation therapeutic area. Supports development of medical research questions and data analyses and partnering with external experts to discuss publication planning relevant to current unmet medical needs of the Medical community. Leads publication idea/concept generation, manages a publication team and ensure reliability and timely dissemination of all publications at both scientific meetings and medical journals. Maintains a comprehensive knowledge of the data relating to the Enbrel (an anti-TNF biologic therapy for immune-mediated diseases) therapeutic area, including those generated from Pfizer-sponsored research as well as those in the scientific literature. Serves as the technical expert for the product(s) and the therapeutic area.

Medical Director provides medical and clinical expertise and leadership specific to the Inflammation therapeutic area.Maintainces a comprehensive knowledge of the data relating to ENBREL, including those generated from Pfizer-sponsored research as well as those in the scientific literature. Serves as the technical expert for ENBREL and leads the publication team to ensure appropriate communication of emerging scientific data to scientific and medical community. Support the development of strategies for clinical research and data generation; is accountable for ensuring that medical plans support the goal of providing clinicians the best treatment options to patients.Partners with external experts to inform scientific planning and clinical development.

2011-2015- Co-lead ( with Arpita Maiti, PhD.,) the organization of Boston 2015 World Congress on Inflammation, under the Auspices of the IAIS and the IRA2011- 2013- Past President and member of Steering Committee ; Scientific advisor for World Congress on Inflammation , Natal, Brazil 2013,

Position had 2 key roles: First to proactively and decisively lead multi-functional early development teams tasked with progressing compounds targeted for Immune-mediated Inflammatory diseases, through to Proof of Concept and secondly, act as the Immunology Therapeutic Laison to the Pulmonary and Inflammation Discovery team, influencing target identification and characterization, biomarker validation and lead candiate optimization and selection prior to entry into early development.

Provide leadership to a cross functional project teams for the global development and execution of the compound strategy; supervizing and facilitating development plan implementation maintaining alignment of strategies for the compound/brand. Champions the product and is prime communicator on all project matters, at all levels. Support therapeutic area focus with role in business development, portfolio alignment and commercialization.• Led 8 individual project development teams progressing small molecule and protein assets targeted for oncology, osteoporosis, osteoarthritis, wound healing and/or metastatic bone disease. Integrated translational medicine strategy to assess target engagement and/or clinical efficacy.• Filed 7 US regulatory INDs, completed 2 proof of concept trials and facilitated the creation and approval of 2 late phase development plans. Received a number of “Impact Awards” 2 of which were significant cash awards for excellent and innovative project progression• Managed contractual obligation and partnership for 3 project alliance partners and contributed to due diligence teams for in-licensing opportunities• Organized, as Excecutive Chair, the 2003 World Congress on Inflammation (WCI) in VanCouver, Can., attended by over 1000 participants and producing $100,000 for re-distibution onto the IRA and IAIS budget• Established and identified funding for the “Woman In Inflammation Science Award”, awarded at the WCI

Provide leadership, strategic guidance to Senior Investigators and their staff, focusing on identification,validation and characterization of novel targets in pulmonary and autoimmune diseases, both small molecule compounds and therapeutic proteins. Facilitate compound progression and creation of robust support packages to de-risk entry into development. Participate in key strategic activities, including establishment of therapeutic disease area strategy and portfolio enhancements through in-licensing and key platform collaborative agreements.• Published over 90 peer reviewed manuscripts and 10 patents. Established numerous collaborations to augment scientific knowledge and characterization of novel gene products. • Mentored up to 40 research scientists in the identification and validation of novel gene targets. Established Immunology cell sorting and FACCs analysis platform.• Progressed multiple programs resulting in advancement of 4 novel agents (3 protein, 1 small molecule) as anti-asthma/allergy therapeutics into development.• Strategic influencer of the Inflammation and Tissue Repair Therapeutic area, • Elected president of the Inflammation Research Association (IRA). Chaired the organizing committee for the 2000 Biennal International IRA (4 Day) meeting. Sample Publications and Patents Suppression of monocyte 85 kDa-phospholipase A2 by antisense and effects on endotoxin-induced prostaglandin biosynthesis. Journal of Biology and Chemistry 269:25999-26005, 1994.CBP kinase inhibitors (CSAIDs) reduce CD23 protein expression on activated monocyte cell surface. Journal of Immunology 161:6005-6013, 1998The human polo-like kinase, PLK1, regulates cdc2/cyclinB through phosphorylation and activation of the cdc25C phosphatase. Cellular Signaling, pp 405-411, 2000 Animal Models of Inflammation Second Edition, Birkhauser, Basel ,2006 EP835937, EP835937 - A human homolog of the MYT1 kinase of Xenopus and a cDNA encoding it,

Conducted research in lipids and eicosanoid biochemistry for anti-inflammatory drug development.